USNA USANA Health Sciences, Inc. Common Stock
NYSE · Consumer products · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 13, 2026USNA Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
USNA Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
| Date ex-dividende | Division | Type |
|---|---|---|
| 23 novembre 2016 | 2-for-1 | Avant |
| 31 octobre 2003 | 2-for-1 | Avant |
| 4 août 1998 | 2-for-1 | Avant |
À propos de USANA Health Sciences, Inc. Common Stock Présentation de l'entreprise depuis Wikipedia
USANA Health Sciences, Inc., or USANA, is an American direct sales company based in Salt Lake City, Utah. As of 2021, USANA was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 25 countries via a network of independent distributors.
History
In 1992, immunologist and microbiologist Myron Wentz moved his diagnostic testing company, Gull Laboratories, from Salt Lake City to West Valley City, Utah, and spun it into USANA Health Services, a multilevel marketing manufacturer of supplements. Beginning in 1993, Dallin A. Larsen served as USANA's vice president of sales (and later as a consultant to USANA's president and special advisor to the board of directors) before founding the MLM beverage company Monavie in 2005. USANA's products are not available through retail channels, and can only be obtained through one of its brand partnersor by direct order through the company.
On 20 February 2007, Barry Minkow, founder of the Fraud Discovery Institute, distributed a 500-page report to officials at the U.S. Securities and Exchange Commission (SEC), the Federal Bureau of Investigation (FBI), and the Internal Revenue Service (IRS) accusing USANA of operating an illegal pyramid scheme. The SEC conducted an investigation into USANA's business practices in March 2007 and found no evidence of wrongdoing, concluding its inquiry with no enforcement action recommended. Minkow acknowledged that he was shorting USANA's shares, hoping to profit from a drop in the stock price. In April 2007, a class action lawsuit was filed alleging that USANA's common stock had been artificially inflated. In August 2007, USANA was notified by the Securities and Exchange Commission (SEC) that its shares were subject to delisting from the NASDAQ due to its Form 10-Q, and was determined to be in compliance that October.
In January 2008, a shareholder suit was filed with allegations that USANA had misled investors about the sustainability of its growth and business model. The cases were dismissed, and the company was cleared by the U.S. Securities and Exchange Commission after an informal inquiry into the allegations, stating that it did "not intend to recommend any enforcement action by the Commission." Later that year, two Canadian USANA distributors were awarded $7 million in damages for their wrongful dismissal from the company. The firm had terminated their positions in 2003 because it believed the distributor had violated the companies' policies and procedures.
USANA filed suits against Minkow and his company claiming defamation and stock manipulation. USANA dropped the defamation suit and in March 2008 U.S. District Judge Tena Campbell threw out four of the five claims brought by USANA against Minkow ruling that USANA's claims violated California's anti-SLAPP law for suing Minkow for fair criticism and that USANA did not show a reasonable probability of winning on those claims. The remaining charge of stock manipulation was settled in July 2008, when USANA and Minkow reached an undisclosed settlement that included the removal of all USANA-related materials from the Fraud Discovery Institute website, a related Chinese website, and YouTube. Minkow also agreed to never trade in USANA's stock again.
In December 2010, USANA completed the application process to transfer its common stock listing from the NASDAQ National Market System, where it had traded since 1996, to the New York Stock Exchange. The transfer became official at the beginning of 2011. It received drug-establishment registration from the Food and Drug Administration to manufacture over-the-counter drugs later that year. In 2012, 91% of product sales were purchased by associates. The company acquired BabyCare Ltd., a China-based prenatal supplement company, in 2013 and announced plans to build a manufacturing facility in the country.
By 2018, USANA had reported record revenue due to growth in the Asia-Pacific region, though it recorded a 7% drop in net sales during its 2019 annual report. USANA has partnered with HealthCorps on health education for children and, in 2019, the USANA Foundation's Kids Eat program opened a facility to pack and distribute food for childhood hunger in the Utah area. In 2026, the Kids Eat program continued efforts to address childhood food insecurity in Utah by providing food bags to students and allowing businesses, families, and other organizations to sponsor participating schools. It was also announced as the official nutritional partner of the Spartan Race endurance brand in the United States. Its sales for the first quarter of 2020 declined by 2.3 percent compared with 2019 numbers.
The USANA Foundation was founded in 2012 and has provided hundreds of millions of meals in more than 45 countries. Their programs include USANA Kids Eat and the USANA Garden Towers.
In February 2019, the Ministry of Commerce in China suspended operations of all multi-level marketing companies and participants to conduct a 100-day review of the country's health foods industry due to exaggerated advertising claims and questionable products in the unregulated sector. Chinese departments initiated "Hundred Days of Action" to clean up the health market, where 49 products from various companies were revoked, 54 food business licenses of various companies were revoked, 90 business licenses of various companies were revoked, and 465 counterfeit and fake dens were destroyed. 85 companies, including BabyCare Ltd., a USANA subsidiary, signed a declaration to self-discipline and regulate operations, with BabyCare speaking at an event hosted by the Chinese government.
In 2024, USANA acquired a 79% stake in children's health and wellness company Hiya Health in a $260 million transaction, making Hiya a subsidiary of USANA. At the time of the acquisition, Hiya had grown to approximately $100 million in annual sales and offered eight children's health products, including multivitamins, probiotics, iron supplements, and immune support products.
Corporate affairs
Leadership
In 2007, USANA faced repeated controversy after members of its board of directors, medical advisory board and several of its executives made false statements regarding their qualifications, including education and licenses.
Founder Myron Wentz was the company's chief executive officer from 1992 until 2008, when his son, Dave Wentz, succeeded him after working in positions such as president, executive vice president, and senior vice president of strategic development. In 2015, USANA announced that the chief executive officer role would be divided between Wentz and Kevin Guest, with the former taking global operations and the latter, field development and sales. Guest was appointed the sole chief executive officer in November 2016.
Operations
USANA, a multilevel marketing company, sells its products primarily through non-employee Brand Partners, as well as through the Internet. The firm's 2010 income disclosure statement defines "associates" as those who are actively building a business, acting as wholesale buyers, or are new distributors. The firm's 2009 SEC 10-K filing distinguishes between associates and preferred customers. Associates are independent distributors of USANA products and also purchase them for personal use. Preferred customers may purchase products at wholesale prices strictly for personal use and are not permitted to resell or distribute them. As of July 2011, the firm had 222,000 active Associates and 68,000 preferred customers. It manufactured 90% of its products at the Salt Lake City headquarters, which produced more than 22 million tablets each week.
Associates may be eligible to receive commissions based on their own product sales as well as through sales made by any new distributors they recruit. According to documentation from USANA corporate, 87 percent of associates fail to make enough from commissions to recover the cost of their qualifying purchases with 67 percent of all associates making no commission; the top 2.31 percent of associates earns 72.2 percent of the company's commissions. According to a 2011 article published by the Salt Lake City Tribune, the firm's FY09 income disclosure statement indicated that the average yearly income of the company's 165,710 associates, which includes those just starting, was $617, while the "top-of-the-pyramid distributors earn an average of $857,865 annually".
USANA sells nutritional, personal care, and food products through Brand Partners and online channels.
USANA classifies Brand Partners and Preferred Customers in its core nutritional business as active customers. There were 387,000 active customers as of January 2026. In 2025, Brand Partners and Preferred Customers each made up about half of all active customers.
Sponsorships
USANA has been a paid sponsor of various athletic organizations. USANA offers an "Athlete Guarantee Program" to select sponsored athletes. The program permits selected participants to enter into an agreement with the company stipulating that, should an athlete enrolled in the program test positive for a banned substance (included in World Anti-Doping Agency regulations) as a result of taking USANA products, the company will compensate the athlete up to two times his or her current annual earnings up to $1 million USD.
In 2006, USANA signed a co-sponsorship agreement with the WTA Tour and extended it in 2011. The agreement provides athletes with nutritional supplements that are guaranteed to conform to the Tour's antidoping policy. As part of the agreement in 2011, USANA donated $1 to Children's Hunger Fund for every ace scored at a WTA tournament beginning at Wimbledon and continuing through the end of the season. USANA provided its products to 40 athletes at the Turin Olympics and worked with various sports organizations, including the Professional Rodeo Cowboys Association.
In 2003, USANA became the title sponsor of the USANA Amphitheatre, an outdoor amphitheatre based in West Valley City, Utah with a seating capacity of 20,000. In May 2012, United Concerts announced a continued naming rights partnership with USANA Health Sciences through March 2018.
In 2020, USANA became the title partner of U.S. Ski & Snowboard's training and education facility, the Center of Excellence. The facility is a training hub used by Olympians, youth athletes, and various international competitions.
In the lead-up to the 2020 Summer Olympics, USANA announced partnerships with USA Swimming and the USA Skateboarding National Team. It was the official multivitamin sponsor of USA Swimming and official nutritional supplement supplier of USA Skateboarding. The partnerships reportedly extended into multi-year agreements.
Products
USANA produces three product lines: USANA Nutritionals (Cellsentials, Optimizers, and Digestion/Detox nutritional supplements), USANA Diet & Energy (Reset meal replacement shakes, protein bars, and Rev3 energy drinks), and Sensé & Celavive personal care (skin care, skin treatment, and hair & body care products).
USANA Essentials were tested in 2011 by ConsumerLab.com in its Multivitamin and Multimineral Supplements Review of 38 leading multivitamin/multimineral products sold in the U.S. and Canada. The Essentials passed ConsumerLab's test, which included testing of selected index elements, their ability to disintegrate in solution per United States Pharmacopeia guidelines, lead contamination threshold set in California Proposition 65, and meeting U.S. Food and Drug Administration (FDA) labeling requirements.
USANA began using InCelligence Technology in August 2016 and registered it as a U.S. trademark in March 2017. The technology is used in the company's CellSentials nutritional supplement system, including its Core Minerals and Vita-Antioxidant products, which USANA markets as using its InCelligence Complex to support cellular protection and renewal. As of 2019, its products are marketed in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, the United Kingdom, the Caribbean, Puerto Rico, Philippines, France, China, Spain, Italy, Germany, Romania, Denmark, Colombia and Indonesia.
Reception
From 2004 to 2006, USANA was named on Forbes "200 Best Small Companies" list. In 2007, a Forbes article quoted industry experts and government officials who had raised questions about the cost of USANA's supplements and its business practices. Radio-Canada later aired an investigative report that examined the company's products, pricing and "misleading income claims" made to potential associates concerning revenue. It included hidden-camera footage of recruitment and other sessions, which found one group of associates appeared to violate the company's policies and distributor agreements. This contrasted with the Canadian legal requirements for multi-level marketing companies to provide clear, frequent and complete information about the revenue of the typical participant. In addition, the same group of associates were filmed making recommendations for using USANA products to treat illnesses including leukemia.
John Cloud, senior writer for Time Magazine, evaluated nutritional supplements in which he took a regimen of USANA pills, protein bars, powder drinks and psyllium fiber as recommended by the company's online evaluation. Cloud took a blood test before starting the products to measure levels of calcium, protein, sodium, cholesterol, glucose, and other substances, and was then tested again five months after starting the supplement regimen, which included 3,000 pills at a cost of $1,200. The follow-up test revealed a change in only two values; a 75% increase in vitamin D levels (attributed to the vitamin D3 supplement Cloud had been taking) and a 28 mg/dl increase in high-density lipoprotein, which could not be accounted for. Cloud also experienced a placebo response where that act of taking the supplements made him feel more vigorous despite no physiological reasons being present. This response also led to a 10-lb weight gain, as the belief that he was more vigorous led him to make poorer dietary decisions—a phenomenon referred to as the "licensing effect".
New Zealand government statistician for the Commerce Commission, Murray H. Smith, who served as an expert witness in every pyramid scheme case brought by the Commission preceding 10 years, opined in 2008 that very few USANA distributors are likely to become wealthy, and stated, "you can make a very strong argument that this could be a pyramid scheme." When asked by the National Business Review to review the firm's business structure and compensation plan, it was Smith's opinion, from a statistical not legal standpoint, that the firm demonstrated a number of characteristics commonly occurring in pyramid schemes including that most members recoup less than what they pay to participate; that those at the top of the structure are more likely to make more than those on the bottom of the structure; and that as the company grows it will become harder to recruit others. Smith also noted the company's significant turnover in distributors making it necessary to continually recruit.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | USNA | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -7.1moyenne 5 ans ≈19.7 | ≈19.7 | · | · | |
| P/S (TTM) | 0.3moyenne 5 ans ≈1.0 | ≈1.0 | 1.2 | Sous-évalué | |
| P/B (MRQ) | 0.5moyenne 5 ans ≈2.3 | ≈2.3 | 2.4 | Sous-évalué | |
| Cours / FCF (TTM) | -16.8moyenne 5 ans ≈20.5 | ≈20.5 | · | · | |
| Cours / Flux de trésorerie (TTM) | -157.2moyenne 5 ans ≈13.5 | ≈13.5 | 16.8 | Juste valeur | |
| Cours / Actif net tangible (MRQ) | 0.7moyenne 5 ans ≈3.0 | ≈3.0 | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | USNA | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge Brute (TTM) | 76.7%moyenne 5 ans ≈80.5% | ≈80.5% | 66.5% | Premier rang | |
| Marge d'exploitation (TTM) | -1.7%moyenne 5 ans ≈9.4% | ≈9.4% | 3.5% | Faible | |
| Marge EBITDA (TTM) | 2.3%moyenne 5 ans ≈11.2% | ≈11.2% | 3.5% | Faible | |
| Marge avant impôts (TTM) | -1.5%moyenne 5 ans ≈10.0% | ≈10.0% | 4.1% | Faible | |
| Marge nette (TTM) | -4.2%moyenne 5 ans ≈6.0% | ≈6.0% | 3.1% | Faible | |
| ROA (TTM) | -5.5%moyenne 5 ans ≈9.8% | ≈9.8% | 6.7% | Faible | |
| ROE (TTM) | -7.4%moyenne 5 ans ≈13.8% | ≈13.8% | 7.0% | Inférieur à la moyenne | |
| ROIC | 1.9%moyenne 5 ans ≈13.1% | ≈13.1% | 7.9% | Faible |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | USNA | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Ratio de liquidité (MRQ) | 2.7moyenne 5 ans ≈2.5 | ≈2.5 | 2.6 | En ligne | |
| Quick Ratio (Ratio de liquidité réduite) | 1.2moyenne 5 ans ≈1.8 | ≈1.8 | 1.2 | Liquidité solide |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | USNA | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | 8.3%moyenne 5 ans ≈-3.6% | ≈-3.6% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | -2.5%moyenne 5 ans ≈-6.5% | ≈-6.5% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | -4.0% | · | · | · | |
| EPS YoY (BPA Année/Année) | -73.5%moyenne 5 ans ≈-31.0% | ≈-31.0% | · | · | |
| Net Income YoY (Bénéfice net YoY) | -74.4%moyenne 5 ans ≈-32.7% | ≈-32.7% | · | · | |
| EPS CAGR 3Y (TCAC BPA 3 ans) | -45.5%moyenne 5 ans ≈-30.1% | ≈-30.1% | · | · | |
| EPS CAGR 5Y (TCAC BPA 5 ans) | -37.0% | · | · | · | |
| Net Income CAGR 3Y (TCAC Bénéfice net 3 ans) | -46.3%moyenne 5 ans ≈-31.7% | ≈-31.7% | · | · | |
| Net Income CAGR 5Y (TCAC Bénéfice net 5 ans) | -38.7% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | USNA | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 1.2moyenne 5 ans ≈1.5 | ≈1.5 | 1.5 | Faible | |
| Inventory Turnover (Rotation des stocks) | 2.3moyenne 5 ans ≈2.4 | ≈2.4 | 3.2 | Faible | |
| Revenue / Employee (Chiffre d'affaires annuel ÷ employés (effectif déclaré, yfinance). Dérivé — pas un concept SEC-XBRL stocké.) | ≈$589.3K | · | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Jul 20, 2026 | $-0.07 | $0.44 | -116.0% |
| 31 mars 2026 | $0.61 | $0.45 | 35.9% | |
| 31 décembre 2025 | $0.60 | $0.42 | 43.5% | |
| 30 septembre 2025 | $-0.15 | $0.48 | -131.3% | |
| 30 juin 2025 | $0.74 | $0.55 | 34.4% | |
| 31 mars 2025 | $0.73 | $0.71 | 2.2% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $925M | $855M | $921M | $999M | $1.19B | $1.13B | $1.06B | $1.19B | $1.05B | $1.01B | $918M | $790M | |
| Cost of Revenue | $201M | $161M | $177M | $194M | $218M | $209M | $188M | $201M | $179M | $180M | $160M | $141M | |
| Gross Profit | $724M | $693M | $744M | $805M | $969M | $926M | $873M | $989M | $868M | $826M | $759M | $650M | |
| R&D Expense | $11M | $12M | $11M | $12M | $11M | $11M | $10M | $10M | $9M | $9M | $6M | $5M | |
| SG&A Expense | $337M | $263M | $257M | $262M | $279M | $261M | $268M | $275M | $265M | $234M | $209M | $185M | |
| Operating Expenses | $687M | $627M | $651M | $697M | $798M | $749M | $727M | $800M | $735M | $687M | $617M | $534M | |
| Operating Income | $37M | $66M | $93M | $108M | $170M | $176M | $146M | $188M | $133M | $139M | $142M | $116M | |
| Interest Expense | · | · | $262.0K | $192.0K | $57.0K | $507.0K | $66.0K | $36.0K | $46.0K | $444.0K | $15.0K | $129.0K | |
| Interest Income | $2M | $11M | $10M | $4M | $3M | $3M | $5M | $4M | $2M | $1M | $1M | $500.0K | |
| Other Non-op | $3M | $-1M | $7.0K | $-3M | $-2M | $-571.0K | $-335.0K | $-1M | $-3.0K | $-1M | $-174.0K | $-820.0K | |
| Pretax Income | $42M | $76M | $102M | $109M | $171M | $178M | $150M | $192M | $135M | $139M | $143M | $116M | |
| Income Tax | $30M | $34M | $39M | $39M | $54M | $53M | $50M | $65M | $72M | $39M | $48M | $39M | |
| Net Income | $11M | $42M | $64M | $69M | $117M | $125M | $101M | $126M | $63M | $100M | $95M | $77M | |
| EPS (Basic) | $0.58 | $2.20 | $3.31 | $3.60 | $5.78 | $5.89 | $4.44 | $5.24 | $2.57 | $4.14 | $3.72 | $2.90 | |
| EPS (Diluted) | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 | $5.86 | $4.41 | $5.12 | $2.53 | $3.99 | $3.59 | $2.80 | |
| Shares (Basic) | 18,535,000 | 19,103,000 | 19,250,000 | 19,254,000 | 20,146,000 | 21,156,000 | 22,644,000 | 24,105,000 | 24,349,000 | 24,185,000 | 25,460,000 | 26,443,000 | |
| Shares (Diluted) | 18,574,000 | 19,162,000 | 19,345,000 | 19,310,000 | 20,343,000 | 21,256,000 | 22,818,000 | 24,642,000 | 24,708,000 | 25,047,000 | 26,355,000 | 27,377,000 | |
| EBITDA | $70M | $81M | $106M | $121M | $183M | $190M | $161M | $205M | $149M | $152M | $152M | $125M |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $158M | $182M | $330M | $288M | $240M | $312M | $235M | $214M | $247M | $176M | $143M | $111M | |
| Receivables | $4M | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $103M | $70M | $61M | $67M | $98M | $90M | $69M | $82M | $63M | $65M | $66M | $45M | |
| Prepaid Expense | $23M | $28M | $26M | $29M | $27M | $23M | $26M | $33M | $30M | $37M | $35M | $35M | |
| Other Current Assets | $5M | $5M | $6M | $7M | $4M | $5M | $5M | $7M | $5M | $6M | $5M | $6M | |
| Current Assets | $288M | $279M | $418M | $384M | $365M | $425M | $329M | $392M | $340M | $278M | $244M | $191M | |
| PP&E (Net) | $94M | $95M | $100M | $98M | $102M | $100M | $95M | $92M | $103M | $101M | $88M | $71M | |
| PP&E (Gross) | · | · | $212M | $210M | $211M | $199M | $181M | $178M | $177M | $164M | $120M | $114M | |
| Accum. Depreciation | $135M | $130M | $129M | $125M | $122M | $116M | $105M | $96M | $86M | $76M | $71M | $64M | |
| Goodwill | $138M | $144M | $17M | $17M | $18M | $17M | $17M | $17M | $17M | $17M | $17M | $18M | |
| Intangibles | $133M | $152M | $30M | $32M | $30M | $31M | $30M | $32M | $35M | $34M | $38M | $41M | |
| Other Non-current Assets | $62M | $59M | $55M | $55M | $58M | $62M | $43M | $18M | $21M | $22M | $25M | $24M | |
| Total Assets | $743M | $748M | $633M | $597M | $578M | $641M | $517M | $554M | $519M | $471M | $423M | $351M | |
| Accounts Payable | $17M | $12M | $10M | $11M | $14M | $18M | $13M | $10M | $12M | $9M | $10M | $8M | |
| Accrued Liabilities | $10M | $14M | $10M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $129M | $140M | $119M | $144M | $161M | $168M | $136M | $149M | $141M | $138M | $131M | $109M | |
| Capital Leases | $12M | $10M | $5M | $8M | $10M | · | $17M | · | · | · | · | · | |
| Deferred Tax | $5M | $4M | $5M | $4M | $7M | $12M | $10M | $13M | $14M | $5M | $10M | $11M | |
| Other Non-current Liabilities | $23M | $18M | $12M | $14M | $14M | $19M | $19M | $1M | $1M | $1M | $1M | $1M | |
| Total Liabilities | $157M | $162M | $136M | · | · | · | · | · | · | · | · | · | |
| Common Stock | $18.0K | $19.0K | $19.0K | $19.0K | $19.0K | $21.0K | $22.0K | $24.0K | $24.0K | $24.0K | $25.0K | $13.0K | |
| Retained Earnings | $466M | $479M | $445M | $392M | $345M | $383M | $306M | $330M | $288M | $265M | $215M | $166M | |
| AOCI | $-16M | $-23M | $-14M | $-13M | $458.0K | $-4M | $-14M | $-10M | $-1M | $-12M | $-4M | $2M | |
| Stockholders' Equity | $533M | $532M | $497M | $434M | $395M | $442M | $352M | $391M | $363M | $325M | $281M | $230M | |
| Liabilities + Equity | $743M | $748M | $633M | $597M | $578M | $641M | $517M | $554M | $519M | $471M | $423M | $351M | |
| Shares Outstanding | 18,281,000 | 19,064,000 | 19,130,000 | 19,206,000 | 19,393,000 | 21,038,000 | 21,655,000 | 23,567,000 | 24,024,000 | 24,485,000 | 24,976,000 | 25,266,000 |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $33M | $15M | $13M | $13M | $13M | $14M | $15M | $17M | $16M | $13M | $10M | $9M | |
| Stock-based Comp | $14M | $15M | $15M | $13M | $14M | $14M | $16M | $15M | $15M | $17M | $11M | $10M | |
| Deferred Tax | $-7M | $-7M | $-3M | $-7M | $-3M | $-2M | $-4M | $607.0K | $19M | $-4M | $-3M | $-1M | |
| Amort. of Intangibles | $19M | $2M | $2M | $2M | $1M | $1M | $1M | $2M | $1M | $2M | $900.0K | $431.0K | |
| Restructuring | $6M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-28M | $-3M | $-18M | $15M | $-20M | $10M | $-442.0K | $-7M | $10M | $11M | $-2M | $11M | |
| Operating Cash Flow | $22M | $61M | $71M | $104M | $121M | $160M | $127M | $152M | $124M | $137M | $111M | $105M | |
| CapEx | $14M | $10M | $14M | $10M | $13M | $15M | $17M | $11M | $13M | $33M | $24M | $20M | |
| Investing Cash Flow | $-10M | $-213M | $-12M | $-12M | $-14M | $-34M | $47M | $-69M | $-13M | $-32M | $-25M | $-16M | |
| Stock Repurchased | $28M | $9M | $12M | $25M | $178M | $57M | $150M | $105M | $50M | $65M | $61M | $139M | |
| Net Stock Activity | $-28M | $-9M | $-12M | $-25M | $-178M | $-57M | $-150M | $-105M | $-50M | $-65M | $-61M | $-139M | |
| Financing Cash Flow | $-41M | $10M | $-14M | $-30M | $-181M | $-59M | $-152M | $-105M | $-50M | $-65M | $-49M | $-113M | |
| Net Change in Cash | $-23M | $-149M | $42M | $48M | $-72M | $78M | $20M | $-33M | $72M | $32M | $32M | $-26M | |
| Taxes Paid | $37M | $40M | $42M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $9M | $51M | $56M | $94M | $108M | $145M | $110M | $141M | $111M | $104M | $88M | $85M | |
| Levered FCF | · | · | $56M | $93M | $108M | $145M | $110M | $141M | $111M | $104M | $88M | $85M |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 81.1% | 80.8% | 80.6% | 81.6% | 81.6% | 82.3% | 83.1% | 82.9% | 82.1% | 82.6% | 82.2% | |
| Operating Margin | 4.0% | 7.8% | 10.1% | 10.8% | 14.3% | 15.6% | 13.8% | 15.8% | 12.7% | 13.8% | 15.4% | 14.7% | |
| Net Margin | 1.2% | 4.9% | 6.9% | 6.9% | 9.8% | 11.0% | 9.5% | 10.6% | 6.0% | 9.9% | 10.3% | 9.7% | |
| Pretax Margin | 4.5% | 8.9% | 11.1% | 10.9% | 14.4% | 15.7% | 14.2% | 16.1% | 12.9% | 13.8% | 15.5% | 14.6% | |
| EBITDA Margin | 7.6% | 9.5% | 11.5% | 12.1% | 15.4% | 16.8% | 15.2% | 17.2% | 14.2% | 15.1% | 16.5% | 15.8% | |
| ROA | 1.4% | 6.1% | 10.4% | 11.8% | 19.1% | 21.5% | 18.8% | 23.5% | 12.6% | 22.4% | 24.5% | 21.3% | |
| ROE | 2.0% | 7.9% | 13.2% | 16.4% | 29.3% | 30.0% | 30.2% | 30.5% | 17.2% | 33.0% | 37.0% | 31.2% | |
| ROIC | 1.9% | 6.9% | 11.7% | 15.8% | 29.4% | 28.0% | 27.8% | 31.7% | 16.9% | 30.8% | 33.5% | 33.4% |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.0 | 3.5 | 2.7 | 2.3 | 2.5 | 2.4 | 2.6 | 2.4 | 2.0 | 1.9 | 1.8 | |
| Quick Ratio | 1.2 | 1.3 | 2.8 | 2.0 | 1.5 | 1.9 | 1.7 | 1.4 | 1.8 | 1.3 | 1.1 | 1.0 | |
| Interest Coverage | · | · | 355.2 | 560.5 | 2985.8 | 348.1 | 2215.0 | 5232.0 | 2880.5 | 312.2 | 9444.1 | 900.0 |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.2 | 1.2 | 1.5 | 1.7 | 1.9 | 2.0 | 2.0 | 2.2 | 2.1 | 2.3 | 2.4 | 2.2 | |
| Inventory Turnover | 2.3 | 2.5 | 2.7 | 2.3 | 2.3 | 2.2 | 2.5 | 2.8 | 2.8 | 2.8 | 2.9 | 3.0 |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $29.16 | $27.91 | $25.99 | $22.62 | $20.37 | $20.99 | $16.24 | $16.60 | $15.12 | $13.29 | $22.49 | $18.22 | |
| Revenue / Share | $49.81 | $44.59 | $47.61 | $51.71 | $58.32 | $53.38 | $46.49 | $48.26 | $42.39 | $40.17 | $69.70 | $57.74 | |
| Cash Flow / Share | $1.20 | $3.18 | $3.65 | $5.38 | $5.96 | $7.55 | $5.55 | $6.17 | $5.01 | $5.47 | $8.46 | $7.68 | |
| Cash / Share | $8.66 | $9.53 | $17.27 | $15.02 | $12.37 | $14.83 | $10.84 | $9.09 | $10.29 | $7.18 | $11.47 | $8.80 | |
| EPS (TTM) | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 | $5.86 | $4.41 | $5.12 | $2.53 | $3.99 | $3.59 | $2.80 |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.3% | -7.2% | -7.8% | -15.8% | 4.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.5% | -10.4% | -6.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -4.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.5% | -33.6% | -8.1% | -37.4% | -2.2% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -45.5% | -27.4% | -17.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -37.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.4% | -34.1% | -8.0% | -40.5% | -6.5% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -46.3% | -28.8% | -20.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -38.7% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $925M | $855M | $921M | $999M | $1.19B | $1.13B | $1.06B | $1.19B | $1.05B | $1.01B | $918M | $790M | |
| Net Income TTM | $11M | $42M | $64M | $69M | $117M | $125M | $101M | $126M | $63M | $100M | $95M | $77M | |
| Market Cap | $355M | $680M | $1.03B | $1.02B | $1.96B | $1.62B | $1.73B | $2.71B | $1.78B | $1.50B | $798M | $646M | |
| P/E | 33.5 | 16.3 | 16.2 | 14.8 | 17.7 | 13.2 | 18.1 | 22.5 | 29.3 | 15.3 | 17.8 | 18.3 | |
| P/S | 0.4 | 0.8 | 1.1 | 1.0 | 1.7 | 1.4 | 1.6 | 2.3 | 1.7 | 1.5 | 0.9 | 0.8 | |
| P/B | 0.7 | 1.3 | 2.1 | 2.4 | 5.0 | 3.7 | 4.9 | 6.9 | 4.9 | 4.6 | 2.8 | 2.8 | |
| P / Tangible Book | 1.4 | 2.9 | 2.3 | 2.7 | 5.7 | 4.1 | · | · | · | · | · | · | |
| P / Cash Flow | 15.9 | 11.2 | 14.5 | 9.8 | 16.2 | 10.1 | 13.7 | 17.8 | 14.4 | 10.9 | 7.2 | 6.1 | |
| P / FCF | 41.7 | 13.4 | 18.3 | 10.9 | 18.1 | 11.2 | 15.7 | 19.3 | 16.1 | 14.4 | 9.1 | 7.6 | |
| Earnings Yield | 3.0% | 6.1% | 6.2% | 6.8% | 5.7% | 7.6% | 5.5% | 4.5% | 3.4% | 6.5% | 5.6% | 5.5% |
Compte de résultat
| Métrique | Tendance | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $223M | $250M | $240M | $214M | $236M | $250M | $214M | $200M | $213M | $228M | $221M | $213M | $248M | $153M | |
| Cost of Revenue | $48M | $59M | $59M | $49M | $50M | $52M | $39M | $39M | $40M | $43M | $42M | $43M | $49M | $35M | |
| Gross Profit | $175M | $191M | $181M | $165M | $186M | $197M | $175M | $161M | $173M | $185M | $179M | $171M | $200M | $118M | |
| SG&A Expense | $82M | $88M | $103M | $86M | $82M | $91M | $73M | $61M | $64M | $64M | $59M | $63M | $67M | $55M | |
| Operating Expenses | $195M | $177M | $191M | $164M | $169M | $181M | $167M | $145M | $155M | $160M | $155M | $153M | $173M | $117M | |
| Operating Income | $-20M | $14M | $-11M | $1M | $17M | $16M | $8M | $16M | $18M | $25M | $24M | $18M | $27M | $984.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $52.0K | · | $43.0K | $31.0K | · | |
| Interest Income | $595.0K | $437.0K | $-2M | $578.0K | $619.0K | $723.0K | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | |
| Other Non-op | $501.0K | $1M | $113.0K | $41.0K | $2M | $756.0K | $-390.0K | $-86.0K | $-349.0K | $-186.0K | $-368.0K | $234.0K | $-88.0K | $-852.0K | |
| Pretax Income | $-19M | $15M | $-13M | $2M | $19M | $17M | $10M | $19M | $20M | $27M | $27M | $21M | $29M | $2M | |
| Income Tax | $9M | $9M | $6M | $8M | $8M | $7M | $6M | $8M | $10M | $11M | $10M | $9M | $10M | $5M | |
| Net Income | $-21M | $8M | $-19M | $-7M | $10M | $9M | $4M | $11M | $10M | $17M | $17M | $11M | $18M | $-3M | |
| EPS (Basic) | $-1.16 | $0.41 | $-0.99 | $-0.36 | $0.52 | $0.49 | $0.23 | $0.56 | $0.55 | $0.86 | $0.87 | $0.59 | $0.95 | $-0.03 | |
| EPS (Diluted) | $-1.16 | $0.41 | $-0.99 | $-0.36 | $0.52 | $0.49 | $0.23 | $0.56 | $0.54 | $0.86 | $0.87 | $0.59 | $0.95 | $-0.01 | |
| Shares (Basic) | 18,486,000 | 18,398,000 | · | 18,293,000 | 18,513,000 | 19,049,000 | · | 19,078,000 | 19,073,000 | 19,174,000 | · | 19,245,000 | 19,283,000 | · | |
| Shares (Diluted) | 18,486,000 | 18,411,000 | · | 18,293,000 | 18,536,000 | 19,085,000 | · | 19,083,000 | 19,159,000 | 19,302,000 | · | 19,372,000 | 19,328,000 | · | |
| EBITDA | $-12M | $22M | · | $9M | $24M | $24M | · | $16M | $18M | $28M | · | $18M | $30M | · |
Bilan
| Métrique | Tendance | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $169M | $163M | $158M | $145M | $151M | $180M | $182M | $365M | $332M | $328M | $330M | $307M | $295M | $288M | |
| Receivables | $3M | $10M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $86M | $96M | $103M | $91M | $83M | $74M | $70M | $64M | $62M | $61M | · | $60M | $64M | · | |
| Prepaid Expense | $23M | $25M | $27M | $28M | $27M | $28M | $28M | $22M | $25M | $32M | · | $23M | $36M | · | |
| Other Current Assets | · | · | $5M | · | · | · | $5M | · | · | · | · | · | · | · | |
| Current Assets | $281M | $294M | $288M | $264M | $262M | $281M | $279M | $451M | $419M | $421M | · | $390M | $396M | · | |
| PP&E (Net) | $94M | $95M | $94M | $96M | $97M | $94M | $95M | $98M | $98M | $98M | · | $95M | $97M | · | |
| Accum. Depreciation | · | · | $135M | · | · | · | $130M | · | · | · | · | · | · | · | |
| Goodwill | $109M | $138M | $138M | $144M | $144M | $144M | $144M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | |
| Intangibles | $125M | $129M | $133M | $138M | $143M | $147M | $152M | $29M | $29M | $29M | · | $29M | $32M | · | |
| Other Non-current Assets | $65M | $58M | $62M | $60M | $63M | $61M | $59M | $59M | $51M | $53M | · | $54M | $56M | · | |
| Total Assets | $703M | $739M | $743M | $727M | $735M | $747M | $748M | $671M | $631M | $629M | · | $601M | $606M | · | |
| Accounts Payable | $15M | $16M | $17M | $16M | $18M | $14M | $12M | $7M | $7M | $8M | · | $9M | $11M | · | |
| Accrued Liabilities | · | · | $10M | · | · | · | $14M | · | · | · | · | · | · | · | |
| Current Liabilities | $106M | $117M | $129M | $119M | $122M | $137M | $140M | $115M | $104M | $113M | · | $113M | $130M | · | |
| Capital Leases | · | · | $12M | · | · | · | $10M | · | · | · | · | · | · | · | |
| Deferred Tax | $5M | $5M | $5M | $4M | $5M | $5M | $4M | $5M | $5M | $5M | · | $5M | $6M | · | |
| Other Non-current Liabilities | $22M | $22M | $23M | $22M | $23M | $21M | $18M | $19M | $11M | $12M | · | $13M | $14M | · | |
| Total Liabilities | $132M | $144M | $157M | $145M | $149M | $163M | $162M | · | · | · | · | · | · | · | |
| Common Stock | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | · | $19.0K | $19.0K | · | |
| Retained Earnings | $452M | $473M | $466M | $467M | $474M | $478M | $479M | $474M | $464M | $453M | · | $428M | $410M | · | |
| AOCI | $-14M | $-14M | $-16M | $-19M | $-19M | $-23M | $-23M | $-14M | $-21M | $-19M | · | $-20M | $-11M | · | |
| Stockholders' Equity | $526M | $544M | $533M | $528M | $531M | $530M | $532M | $533M | $512M | $500M | $497M | $470M | $455M | $434M | |
| Liabilities + Equity | $703M | $739M | $743M | $727M | $735M | $747M | $748M | $671M | $631M | $629M | · | $601M | $606M | · | |
| Shares Outstanding | 18,463,000 | 18,457,000 | 18,281,000 | 18,272,000 | 18,262,000 | 18,786,000 | 19,064,000 | 19,056,000 | 19,051,000 | 19,047,000 | 19,130,000 | 19,122,000 | 19,294,000 | 19,206,000 |
Flux de trésorerie
| Métrique | Tendance | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $8M | $8M | $13M | $8M | $8M | $8M | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | |
| Stock-based Comp | $3M | $3M | $3M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | |
| Other Non-cash | · | · | · | · | · | $-5M | · | · | · | $-6M | · | · | $-12M | · | |
| Operating Cash Flow | $23M | $10M | $-33M | $-2M | $12M | $15M | $6M | $28M | $8M | $18M | $26M | $22M | $13M | $40M | |
| CapEx | $3M | $3M | $6M | $3M | $5M | $3M | $2M | $441.0K | $3M | $3M | $7M | $1M | $2M | $3M | |
| Investing Cash Flow | $-4M | $-3M | $-2M | $-3M | $-4M | $-4M | $-205M | $85.0K | $-2M | $-4M | $-7M | $-1M | $-3M | $-3M | |
| Stock Repurchased | $0 | $0 | $18M | $0 | $15M | $12M | $0 | $-18M | $0 | $9M | $0 | $12M | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | $-12M | · | · | · | $-9M | · | · | $0 | · | |
| Financing Cash Flow | $-14M | $-4M | $-27M | $-979.0K | $-39M | $-14M | $23M | $40M | $-1M | $-12M | $658.0K | $-12M | $-3M | $-150.0K | |
| Net Change in Cash | $6M | $4M | $-58M | $-6M | $-28M | $-2M | $-183M | $65M | $4M | $-2M | $23M | $7M | $7M | $41M | |
| Free Cash Flow | · | $7M | · | · | · | $13M | · | · | · | $14M | · | · | $11M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $14M | · | · | $11M | · |
Rentabilité
| Métrique | Tendance | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 76.2% | · | 77.1% | 78.7% | 79.0% | · | 80.4% | 81.0% | 81.1% | · | 80.1% | 80.5% | · | |
| Operating Margin | -9.0% | 5.5% | · | 0.57% | 7.1% | 6.3% | · | 7.8% | 8.4% | 10.8% | · | 8.2% | 10.8% | · | |
| Net Margin | -9.6% | 3.0% | · | -3.0% | 4.1% | 3.8% | · | 5.3% | 4.9% | 7.3% | · | 5.3% | 7.4% | · | |
| Pretax Margin | -8.5% | 6.2% | · | 0.84% | 8.0% | 6.7% | · | 9.3% | 9.5% | 11.9% | · | 9.6% | 11.5% | · | |
| EBITDA Margin | -5.5% | 8.8% | · | 4.3% | 10.4% | 9.6% | · | 7.8% | 8.4% | 12.2% | · | 8.2% | 12.1% | · | |
| ROA | -3.0% | 1.0% | · | -0.93% | 1.4% | 1.4% | · | 1.7% | 1.7% | 2.7% | · | 2.0% | · | · | |
| ROE | -4.0% | 1.4% | · | -1.2% | 1.8% | 1.8% | · | 2.1% | 2.1% | 3.5% | · | 2.6% | · | · | |
| ROIC | -5.6% | 1.1% | · | -0.86% | 1.8% | 1.6% | · | 1.7% | 1.8% | 3.0% | · | 2.1% | · | · |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 2.5 | · | 2.2 | 2.2 | 2.0 | · | 3.9 | 4.0 | 3.7 | · | 3.5 | · | · | |
| Quick Ratio | 1.6 | 1.5 | · | 1.2 | 1.2 | 1.3 | · | 3.2 | 3.2 | 2.9 | · | 2.7 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 474.5 | · | 409.5 | 866.0 | · |
Efficacité
| Métrique | Tendance | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.4 | · | 0.3 | 0.3 | 0.4 | · | 0.4 | · | · | |
| Inventory Turnover | 0.6 | 0.7 | · | 0.6 | 0.7 | 0.8 | · | 0.6 | 0.7 | 0.7 | · | 0.7 | · | · | |
| Receivables Turnover | 133.8 | 51.8 | · | · | · | · | · | · | · | · | · | · | · | · |
Par action
| Métrique | Tendance | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $28.51 | $29.45 | · | $28.90 | $29.08 | $28.20 | · | $27.97 | $26.89 | $26.25 | · | $24.60 | · | · | |
| Revenue / Share | $12.08 | $13.59 | · | $11.68 | $12.72 | $13.08 | · | $10.49 | $11.11 | $11.80 | · | $11.01 | $12.85 | · | |
| Cash Flow / Share | · | $0.53 | · | · | · | $0.81 | · | · | · | $0.92 | · | · | $0.66 | · | |
| Cash / Share | $9.13 | $8.82 | · | $7.95 | $8.29 | $9.56 | · | $19.15 | $17.45 | $17.24 | · | $16.06 | · | · | |
| EPS (TTM) | $-2.10 | $-0.42 | · | $0.88 | $1.80 | $1.82 | · | $2.83 | $2.86 | $3.21 | · | $2.42 | $2.72 | · |
Valorisation (TTM)
| Métrique | Tendance | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $927M | $939M | · | $913M | $899M | $876M | · | $862M | $875M | $900M | · | $853M | $899M | · | |
| Net Income TTM | $-39M | $-8M | · | $17M | $34M | $35M | · | $54M | $55M | $62M | · | $44M | $50M | · | |
| Market Cap | $397M | $312M | · | $521M | $568M | $522M | · | $723M | $862M | $924M | · | $1.12B | · | · | |
| P/E | -10.2 | -40.2 | · | 32.4 | 17.3 | 15.3 | · | 13.4 | 15.8 | 15.1 | · | 24.2 | 23.1 | · | |
| P/S | 0.4 | 0.3 | · | 0.6 | 0.6 | 0.6 | · | 0.8 | 1.0 | 1.0 | · | 1.3 | 1.3 | · | |
| P/B | 0.8 | 0.6 | · | 1.0 | 1.1 | 1.0 | · | 1.4 | 1.7 | 1.8 | · | 2.4 | · | · | |
| P / Tangible Book | 1.4 | 1.1 | · | 2.1 | 2.3 | 2.2 | · | 1.5 | 1.8 | 2.0 | · | 2.6 | · | · | |
| P / Cash Flow | · | 32.0 | · | · | · | 33.7 | · | · | · | 52.2 | · | · | · | · | |
| Earnings Yield | -9.8% | -2.5% | · | 3.1% | 5.8% | 6.6% | · | 7.5% | 6.3% | 6.6% | · | 4.1% | 4.3% | · |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2026-01-03 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2022-01-01 |
|---|---|---|---|---|---|
| Revenu | $925M | $855M | $921M | $999M | $1.19B |
| Marge Brute % | 78.3% | 81.1% | 80.8% | 80.6% | 81.6% |
| Marge d'exploitation % | 4.0% | 7.8% | 10.1% | 10.8% | 14.3% |
| Résultat net | $11M | $42M | $64M | $69M | $117M |
| BPA dilué | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 |
| Métrique | 2026-01-03 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2022-01-01 |
|---|---|---|---|---|---|
| Ratio de liquidité | 2.2 | 2.0 | 3.5 | 2.7 | 2.3 |
| Ratio de liquidité réduite | 1.2 | 1.3 | 2.8 | 2.0 | 1.5 |
| Métrique | 2026-01-03 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2022-01-01 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $9M | $51M | $56M | $94M | $108M |
Détenteurs institutionnels (13F) 151 déclarants · $260.7M total · Au 30 septembre 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 25 (-5 vs T. préc.) | 17 (+8 vs T. préc.) | 60 (+21 vs T. préc.) | 30 (-19 vs T. préc.) | +1.2M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $33 181 935 | 1 554 189 | 12,73% | Actions |
| PZENA INVESTMENT MANAGEMENT LLC | $25 739 282 | 1 205 587 | 9,87% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $20 464 402 | 958 520 | 7,85% | Actions |
| VANGUARD GROUP INC | $18 340 623 | 934 316 | 7,03% | Actions |
| DIMENSIONAL FUND ADVISORS LP | $17 878 705 | 837 426 | 6,86% | Actions |
| Nantahala Capital Management, LLC | $17 295 080 | 810 074 | 6,63% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $10 405 350 | 487 370 | 3,99% | Actions |
| Creative Planning | $8 923 681 | 417 971 | 3,42% | Actions |
| AQR CAPITAL MANAGEMENT LLC | $8 712 637 | 408 086 | 3,34% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7 758 099 | 363 377 | 2,98% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $6 047 019 | 283 165 | 2,32% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $5 811 641 | 272 208 | 2,23% | Actions |
| STATE STREET CORP | $5 577 474 | 261 240 | 2,14% | Actions |
| Nuveen, LLC | $5 112 835 | 239 477 | 1,96% | Actions |
| AMERICAN CENTURY COMPANIES INC | $3 999 880 | 187 348 | 1,53% | Actions |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $3 855 105 | 180 567 | 1,48% | Actions |
| TWO SIGMA INVESTMENTS, LP | $3 533 724 | 165 514 | 1,36% | Actions |
| MORGAN STANLEY | $3 509 150 | 164 363 | 1,35% | Actions |
| D. E. Shaw & Co., Inc. | $3 348 427 | 156 835 | 1,28% | Actions |
| Allianz Asset Management GmbH | $3 040 219 | 142 399 | 1,17% | Actions |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $2 949 567 | 138 153 | 1,13% | Actions |
| ALGERT GLOBAL LLC | $2 813 033 | 131 758 | 1,08% | Actions |
| GOLDMAN SACHS GROUP INC | $2 631 750 | 123 267 | 1,01% | Actions |
| UBS Group AG | $2 474 166 | 115 886 | 0,95% | Actions |
| LAZARD ASSET MANAGEMENT LLC | $2 077 590 | 97 311 | 0,80% | Actions |
| NORTHERN TRUST CORP | $2 016 870 | 94 467 | 0,77% | Actions |
| AMERIPRISE FINANCIAL INC | $1 552 893 | 72 735 | 0,60% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $1 549 540 | 72 578 | 0,59% | Actions |
| Vanguard Global Advisers, LLC | $1 514 569 | 70 940 | 0,58% | Actions |
| Empowered Funds, LLC | $1 499 902 | 70 253 | 0,58% | Actions |
| TWO SIGMA ADVISERS, LP | $1 289 691 | 65 700 | 0,49% | Actions |
| Bank of New York Mellon Corp | $1 104 521 | 51 734 | 0,42% | Actions |
| Quantinno Capital Management LP | $1 072 261 | 50 223 | 0,41% | Actions |
| BANK OF AMERICA CORP /DE/ | $967 539 | 45 318 | 0,37% | Actions |
| ROYCE & ASSOCIATES LP | $884 039 | 41 407 | 0,34% | Actions |
| DEUTSCHE BANK AG\ | $821 975 | 38 500 | 0,32% | Actions |
| Assenagon Asset Management S.A. | $815 848 | 38 213 | 0,31% | Actions |
| BARCLAYS PLC | $777 141 | 36 400 | 0,30% | Actions |
| STRS OHIO | $723 765 | 33 900 | 0,28% | Actions |
| Skopos Labs, Inc. | $673 696 | 38 563 | 0,26% | Actions |
| HSBC HOLDINGS PLC | $672 758 | 31 960 | 0,26% | Actions |
| Invesco Ltd. | $670 775 | 31 418 | 0,26% | Actions |
| SEI INVESTMENTS CO | $641 513 | 30 047 | 0,25% | Actions |
| XTX Topco Ltd | $625 320 | 29 289 | 0,24% | Actions |
| CITADEL ADVISORS LLC | $575 617 | 26 961 | 0,22% | Actions |
| MILLENNIUM MANAGEMENT LLC | $570 728 | 26 732 | 0,22% | Actions |
| Verdad Advisers, LP | $556 552 | 26 068 | 0,21% | Actions |
| Inspire Investing, LLC | $512 954 | 29 362 | 0,20% | Actions |
| Sanctuary Advisors, LLC | $497 113 | 23 284 | 0,19% | Actions |
| Man Group plc | $489 854 | 22 944 | 0,19% | Actions |
Activistes et détenteurs de 5%+ 3 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Gull Global Limited, Myron W. Wentz ×11 dépôts | 30 mars 2026 | 40,10% | Amendement | Fusions et acquisitions / vente | SEC |
| Gull Holdings, Ltd., Myron W. Wentz, David A. Wentz, Jacquelyn R. Wentz, Bryan Wentz, Annette Wentz, Paul & Jane Meyer Family Foundation, Paul James Meyer, Alice Jane Meyer, Centre Island Properties, Ltd., Waco Boys Club Foundation, Inc., L-K Marketing Group, LLC, Beagle Irrevocable Asset Trust | 23 mai 2008 | · | Dépôt initial | · | SEC |
| Paul & Jane Meyer Family Foundation | 20 mai 2008 | · | Dépôt initial | Investissement passif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Initiés de la société 38 initiés · 20 dirigeants · 13 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jim Brown | CEO & PRESIDENT | 24 juillet 2025 M | 16 934 | 0 | 0 | $0 |
| Doug G Iiekking | CHIEF FINANCIAL OFFICER | 27 mai 2026 S | 0 | 0 | 1 | $-100 500 |
| Jeffrey Yates | Chief Financial Officer | 28 octobre 2010 M | 0 | 0 | 0 | $0 |
| Deborah Woo | President of Asia | 8 septembre 2016 M | 1 479 | 0 | 0 | $0 |
| Fred W Cooper | President and COO | 28 octobre 2010 M | 0 | 0 | 0 | $0 |
| Walter Noot | CHIEF OPERATING OFFICER | 27 février 2026 M | 9 256 | 0 | 0 | $0 |
| Roy Truett | Chief Operating Officer | 27 juillet 2012 M | 0 | 0 | 0 | $0 |
| Kathryn Michelle Armstrong | CHIEF SCIENTIFIC OFFICER | 25 juillet 2026 M | 3 471 | 0 | 0 | $0 |
| Peter Benedict | CHIEF INFORMATION OFFICER | 25 juillet 2026 M | 422 | 0 | 2 | $-144 236 |
| Brent Neidig | CHIEF COMMERCIAL OFFICER | 16 juin 2026 S | 0 | 0 | 3 | $-147 749 |
| Paul A. Jones | CHIEF PEOPLE OFFICER | 8 juin 2026 S | 0 | 0 | 2 | $-231 984 |
| Joshua Foukas | CHIEF LEGAL OFFICER | 7 mai 2026 S | 0 | 0 | 2 | $-170 336 |
| David Mulham Mulham | CHIEF SALES OFFICER | 10 décembre 2025 S | 8 387 | 0 | 1 | $-18 333 |
| Daniel A. Macuga | CHIEF COMMUNICATIONS OFFICER | 2 mai 2024 S | 0 | 0 | 0 | $0 |
| Robert A Sinnott | CHIEF SCIENTIFIC OFFICER | 5 mars 2024 S | 0 | 0 | 0 | $0 |
| James Bramble | Chief Legal Officer and Sec | 5 février 2018 A | 2 076 | 0 | 0 | $0 |
| Dave Wentz | Co-C.E.O. | 16 août 2016 M | 384 883 | 0 | 0 | $0 |
| Rick Stambaugh | Chief Information Officer | 17 décembre 2015 M | 0 | 0 | 0 | $0 |
| Mark H Wilson | E.V.P. of Sales | 28 octobre 2010 M | 5 000 | 0 | 0 | $0 |
| Bradford Richardson | E.V.P. of Asia Pacific | 25 février 2008 S | 0 | 0 | 0 | $0 |
| Xia Ding | Administrateur | 23 juillet 2026 M | 8 278 | 0 | 0 | $0 |
| John Turman Fleming | Administrateur | 23 juillet 2026 M | 5 862 | 0 | 2 | $-78 560 |
| Peggie Pelosi | Administrateur | 23 juillet 2026 M | 6 061 | 0 | 0 | $0 |
| Scott J Nixon | Administrateur | 23 juillet 2026 M | 11 445 | 0 | 0 | $0 |
| Frederic J Winssinger | Administrateur | 23 juillet 2026 M | 9 733 | 0 | 1 | $-38 420 |
| Timothy E Wood | Administrateur | 23 juillet 2026 M | 11 837 | 0 | 0 | $0 |
| Gilbert A Fuller | Administrateur | 23 juillet 2026 M | 1 632 | 0 | 3 | $-60 414 |
| Robert Auciaux | Administrateur | 9 mai 2022 M | 8 092 | 0 | 0 | $0 |
| Feng Peng | Administrateur | 28 avril 2021 M | 755 | 0 | 0 | $0 |
| Myron W. Wentz | Administrateur | 4 février 2019 S | 9 865 614 | 0 | 0 | $0 |
| Jerry G Mcclain | Administrateur | 4 mars 2016 M | 0 | 0 | 0 | $0 |
| Ronald S Poelman | Administrateur | 8 février 2016 A | 0 | 0 | 0 | $0 |
| Denis E Waitley | Administrateur | 3 novembre 2006 M | 0 | 0 | 0 | $0 |
| Gull Global Limited | Détenteur de 10% | 4 février 2019 S | 9 865 614 | 0 | 0 | $0 |
| GULL HOLDINGS LTD | Détenteur de 10% | 1 avril 2015 J | 6 491 110 | 0 | 0 | $0 |
| Kevin Guest | · | 27 février 2026 M | 45 381 | 0 | 0 | $0 |
| Donald R. Williams | · | 1 mai 2017 A | · | 0 | 0 | $0 |
| Doug Braun | · | 16 décembre 2015 M | 0 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 22 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| VFVA · VANGUARD WELLINGTON FUND | 0,11% | 45 046 SH | 19 août 2026 | Quotidien |
| EBIT · Harbor ETF Trust | 0,07% | 367 NS | 31 juillet 2026 | N-PORT |
| IWC · iShares Trust | 0,04% | 37 870 SH | 11 septembre 2026 | Quotidien |
| VDC · VANGUARD WORLD FUND | 0,03% | 128 565 SH | 19 août 2026 | Quotidien |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 9 639 SH | 19 août 2026 | Quotidien |
| DFSV · Dimensional ETF Trust | 0,02% | 67 386 NS | 31 juillet 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 24 234 SH | 1 octobre 2026 | Quotidien |
| DFAT · Dimensional ETF Trust | 0,01% | 67 428 NS | 31 juillet 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 64 278 SH | 19 août 2026 | Quotidien |
| RSSL · Global X Funds | 0,01% | 5 337 NS | 31 juillet 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1 189 SH | 1 octobre 2026 | Quotidien |
| DFAS · Dimensional ETF Trust | 0,01% | 42 099 NS | 31 juillet 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 283 783 SH | 11 septembre 2026 | Quotidien |
| DFAC · Dimensional ETF Trust | 0,00% | 19 278 NS | 31 juillet 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 22 756 SH | 11 septembre 2026 | Quotidien |
| IWV · iShares Trust | 0,00% | 3 720 SH | 3 septembre 2026 | Quotidien |
| DFUS · Dimensional ETF Trust | 0,00% | 1 784 NS | 31 juillet 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 124 681 SH | 19 août 2026 | Quotidien |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 350 035 SH | 19 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 790 SH | 19 août 2026 | Quotidien |
| IWN · iShares Trust | · | 101 470 SH | 11 septembre 2026 | Quotidien |
| SMLF · iShares Trust | · | 22 964 SH | 11 septembre 2026 | Quotidien |
USNA Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
Objectif de cours à 12 mois
1 analystes · 2026-10-01Objectif moyen $25.00 +68,7%
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| USNA | $355M | 33.5 | 8.3% | 1.2% | 2.0% | 78.3% |
| EPC | $946M | 38.4 | -1.3% | 1.1% | 1.7% | 41.6% |
| BRBR | $4.39B | 21.6 | 16.1% | 9.3% | -72.0% | 33.3% |
| HNST | $291M | -18.4 | -1.9% | -4.2% | -8.8% | 33.3% |
| NUS | · | 3.0 | -14.3% | 10.8% | 22.0% | 69.5% |
| NAGE | $507M | 31.8 | 29.9% | 13.4% | 24.7% | 64.3% |
| NATR | $378M | 20.4 | 5.7% | 4.1% | 12.0% | 72.4% |
| MED | $117M | -6.3 | -36.0% | -4.8% | -9.0% | 71.3% |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.